STOCK TITAN

Kura Oncology (KURA) SEC Filings, May-Jun 2026

KURA NASDAQ

Kura Oncology, Inc. filings document a Nasdaq-listed biopharmaceutical company focused on precision medicines for cancer, including disclosures on KOMZIFTI™ (ziftomenib), acute myeloid leukemia programs, darlifarnib (KO-2806) and collaboration activity with Kyowa Kirin. Form 8-K reports cover financial results, FDA approval and product-launch disclosures, clinical program updates, milestone payments and other material events.

Governance filings include the company’s definitive proxy statement for annual meeting matters, director elections, auditor ratification and executive compensation. Other filings describe amendments to bylaws, the 2023 Inducement Option Plan, nonstatutory stock option grants and the company’s common stock listing on The Nasdaq Global Select Market.

Rhea-AI Summary

Kura Oncology reported that director Mary T. Szela received an option grant to purchase 35,000 shares of common stock. The option has an exercise price of $8.77 per share and expires on June 3, 2036. It vests in full on the one-year anniversary of the grant date, and following this award she holds 35,000 options directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
insider
-
Rhea-AI Summary

Kura Oncology director Thomas Malley received a stock option grant covering 35,000 shares of common stock. The option has an exercise price of $8.77 per share and was reported as a grant or award, not an open-market purchase or sale.

The option vests in full on the one-year anniversary of the grant date and expires on June 3, 2036 if not exercised. Following this award, Malley’s reported derivative holdings in this option total 35,000 underlying shares, reflecting a compensation-related equity incentive rather than a discretionary trade.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
insider
-
Rhea-AI Summary

Kura Oncology, Inc. reported results of its Annual Meeting of Stockholders and approval of expanded equity compensation plans. Stockholders approved amendments to the 2014 Equity Incentive Plan adding 6,500,000 shares and to the 2015 Employee Stock Purchase Plan adding 2,500,000 shares for future awards.

As of the April 6, 2026 record date, 88,762,704 shares of common stock were outstanding, and 69,778,580 shares were present or represented by proxy. Stockholders elected three Class III directors to terms ending at the 2029 annual meeting, ratified Ernst & Young LLP as auditor, approved executive compensation on an advisory basis, chose an annual say‑on‑pay vote, and confirmed both the amended equity plan and ESPP.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
current report
Rhea-AI Summary

Kura Oncology, Inc. Chief Commercial Officer Brian T. Powl sold 10,000 shares of common stock in an open-market transaction at $11.00 per share. After the sale, he held 173,614 shares directly. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 18, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.47%
Tags
insider
-
Rhea-AI Summary

KURA reported a proposed sale of 10,000 shares of Common Stock via Form 144.

The filing lists 10,000 shares of restricted stock units to be sold with an aggregate value of $103,400.00 and a filing date of 05/21/2026. The report also discloses 10b5-1 sales of 339 shares on 05/19/2026 for $3,122.19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
other
-
Rhea-AI Summary

Kura Oncology, Inc. Chief Commercial Officer Brian T. Powl reported an open-market sale of 339 shares of common stock at $9.21 per share. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan. Following this sale, he directly holds 183,614 shares of Kura Oncology common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.64%
Tags
insider
Rhea-AI Summary

Kura Oncology, Inc. Chief Operating Officer Kathleen Ford reported an open-market sale of 2,257 shares of common stock on May 19, 2026 at a weighted average price of $9.0752 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2025.

According to the filing, the 2,257 shares sold match 2,257 shares acquired on May 17, 2026 through the company’s Employee Stock Purchase Plan. After this transaction, Ford directly holds 153,560 shares of Kura Oncology common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.64%
Tags
insider
-
Rhea-AI Summary

Kura Oncology, Inc. Chief Legal Officer Teresa Brophy Bair sold 2,256 shares of common stock in an open-market transaction at a weighted average price of $9.3795 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025.

According to the filing, the 2,256 shares sold had been acquired on May 17, 2026 through the company’s Employee Stock Purchase Plan. Following this transaction, Bair directly holds 226,931 shares of Kura Oncology common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.64%
Tags
insider
-
Form 144
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.40%
Tags
other
Form 144
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.40%
Tags
other

FAQ

How many Kura Oncology (KURA) SEC filings are available on StockTitan?

StockTitan tracks 130 SEC filings for Kura Oncology (KURA), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Kura Oncology (KURA)?

The most recent SEC filing for Kura Oncology (KURA) was filed on November 19, 2026.